Hyperhomocyst(e)inaemia: an independent risk factor for intermittent claudication
- PMID: 1556525
- DOI: 10.1111/j.1365-2796.1992.tb00535.x
Hyperhomocyst(e)inaemia: an independent risk factor for intermittent claudication
Abstract
The aim of this study was to test the question of hyperhomocyst(e)inaemia as a risk factor for intermittent claudication (IC) independent of other important risk factors for peripheral atherosclerotic disease, such as smoking, hypertension, diabetes mellitus, hypercholesterolaemia, hypertriglyceridaemia, low levels of high-density-lipoprotein (HLD) cholesterol and age. The study population was recruited from an epidemiological study in Linköping County, Sweden, where all middle-aged men (n = 15,253, 45-69 years of age) were screened for IC. Seventy-eight subjects with verified IC and 98 healthy sex- and age-matched controls were randomly selected. Plasma levels of homocyst(e)ine (including the sum of free and bound forms of homocysteine and their disulphide oxidation products, homocystine, and homocysteine-cysteine mixed disulphide) were significantly higher (16.74 +/- 5.45 mumol l-1, mean value +/- SD, P = 0.0002) in IC subjects than in controls (13.80 +/- 3.21 mumol l-1), with 23% of the claudicants above the 95th percentile for controls. Stepwise logistic regression analysis revealed that the difference in plasma homocyst(e)ine was independent of the other above-mentioned risk factors. Moreover, the elevation of plasma homocyst(e)ine in claudicants was mainly confined to subjects with serum folate levels of less than or equal to 11.0 nmol l-1. The results suggest that folic acid supplementation should be tried in IC subjects with hyperhomocyst(e)inaemia.
Similar articles
-
Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: is homocyst(e)ine the missing link?Nephrol Dial Transplant. 1999 Aug;14(8):1934-42. doi: 10.1093/ndt/14.8.1934. Nephrol Dial Transplant. 1999. PMID: 10462274
-
Hyperhomocyst(e)inaemia in children with chronic renal failure.Nephrol Dial Transplant. 1999 Feb;14(2):366-8. doi: 10.1093/ndt/14.2.366. Nephrol Dial Transplant. 1999. PMID: 10069190
-
Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease.Am J Kidney Dis. 1999 Oct;34(4):669-77. doi: 10.1016/S0272-6386(99)70392-6. Am J Kidney Dis. 1999. PMID: 10516348
-
[Homocysteine, endothelial dysfunction and cardiovascular risk: pathomechanisms and therapeutic options].Z Kardiol. 2001 Jan;90(1):1-11. doi: 10.1007/s003920170206. Z Kardiol. 2001. PMID: 11220081 Review. German.
-
Patients with atherosclerotic vascular disease: how low should plasma homocyst(e)ine levels go?Am J Cardiovasc Drugs. 2001;1(2):85-9. doi: 10.2165/00129784-200101020-00002. Am J Cardiovasc Drugs. 2001. PMID: 14728038 Review.
Cited by
-
Hyperhomocysteinaemia; with reference to its neuroradiological aspects.Neuroradiology. 1995 Jul;37(5):403-11. doi: 10.1007/BF00588024. Neuroradiology. 1995. PMID: 7477843 Review.
-
Homocystinuria: what about mild hyperhomocysteinaemia?Postgrad Med J. 1996 Sep;72(851):513-8. doi: 10.1136/pgmj.72.851.513. Postgrad Med J. 1996. PMID: 8949585 Free PMC article. Review.
-
International validation of the CLAU-S quality-of-life questionnaire for use in patients with intermittent claudication.Pharmacoeconomics. 2001;19(6):667-77. doi: 10.2165/00019053-200119060-00005. Pharmacoeconomics. 2001. PMID: 11456214
-
Increased prevalence of peripheral arterial disease in osteoporotic postmenopausal women.J Bone Miner Metab. 2006;24(2):125-31. doi: 10.1007/s00774-005-0658-8. J Bone Miner Metab. 2006. PMID: 16502119
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources